Ptc Therapeutics (PTCT) Long-Term Deferred Tax (2014 - 2015)
Ptc Therapeutics' (PTCT) quarterly Long-Term Deferred Tax came in at $231.5 million in Q4 2015, little changed year-on-year from $231.5 million in Q4 2014, and little changed quarter-over-quarter from $231.5 million in Q4 2014.
Ptc Therapeutics (PTCT) Long-Term Deferred Tax (2014 - 2015) Analysis & Trends
Ptc Therapeutics' Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $231.5 million for Q4 2015.
- On a quarterly basis, Long-Term Deferred Tax changed 0.0% year-over-year to $231.5 million in Q4 2015; TTM through Dec 2015 was $231.5 million, a 0.0% change from a year earlier, with the FY2015 full-year figure at $231.5 million, changed 0.0% from the prior year.
- Long-Term Deferred Tax was little changed at $231.5 million in Q4 2015 per PTCT's latest filing, from $231.5 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $231.5 million in Q4 2014 and bottomed at $231.5 million in Q4 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Ptc Therapeutics | 6.47 Bn | 4.58 Bn | 244.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 231.50 Mn |
| Dec 31, 2014 | 231.50 Mn |